Casgevy is now approved in the U.S. for children with sickle cell as young as 2, becoming the first gene-editing therapy for ...

When good specialists from a healthcare team move on, it can disrupt a patient's world, writes columnist Mary Shaniqua. But ...

VAS-101, a curcumin-based gel for SCD, was well tolerated and showed signs of easing sickle cell pain, fatigue, and red blood ...

Children with sickle cell anemia who undergo stem cell transplant tend to have better long-term cognition than those on ...

Agios Pharmaceuticals’ medication mitapivat rapidly increased levels of the oxygen-carrying protein hemoglobin in patients ages 16 and older with sickle cell disease (SCD), while also being linked to ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google After completing my finals and passing my clinical comprehensive ...

An experimental, single-dose gene-editing therapy from Tessera Therapeutics successfully corrected the genetic mutation that causes sickle cell disease (SCD) in the majority of blood-forming stem ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google I have often found that my experiences with sickle beta-zero ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The quiet, creeping isolation that comes with living with sickle ...

Clinician bias toward people with sickle cell disease (SCD) may be tied to stigma around opioid use, rather than race or chronic pain alone, a new study suggests. “Although patients with sickle cell ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Children with sickle cell anemia (SCA), the most common and ...

Beam Therapeutics plans to ask the U.S. Food and Drug Administration (FDA) to approve ristoglogene autogetemcel, or risto-cel, its single-dose, gene-edited cell therapy candidate for people with ...